Embecta Corp. (EMBC)
Automate Your Wheel Strategy on EMBC
With Tiblio's Option Bot, you can configure your own wheel strategy including EMBC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EMBC
- Rev/Share 18.6275
- Book/Share -12.7036
- PB -0.7746
- Debt/Equity -2.1074
- CurrentRatio 2.4813
- ROIC 0.1905
- MktCap 575074298.0
- FreeCF/Share 0.685
- PFCF 14.4855
- PE 10.9453
- Debt/Assets 1.385
- DivYield 0.061
- ROE -0.0693
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EMBC | Mizuho | -- | Neutral | -- | $15 | April 10, 2025 |
News
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan (“LRP”).
Read More
Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Anthony Petrone - Mizuho Securities Michael Polark - Wolfe Research Operator Welcome, ladies and gentlemen, to Embecta Corp.'s fiscal second quarter 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode.
Read More
Embecta Corp. (EMBC) Tops Q2 Earnings Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Embecta Corp. (EMBC) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.67 per share a year ago.
Read More
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025.
Read More
embecta Announces Quarterly Cash Dividend
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
Read More
Embecta to host Analyst and Investor Day on May 22, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.
Read More
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product.
Read More
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET.
Read More
About Embecta Corp. (EMBC)
- IPO Date 2022-03-22
- Website https://www.embecta.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Devdatt Kurdikar Ph.D.
- Employees 2000